An improved understanding of the origins and spread of drug-resistant bacteria, as well as the identification of novel antimicrobial compounds and new drug combinations, will facilitate the development of better dosing regimens and novel strategies to manage drug resistance and prevent the dissemination of resistant bacteria.
This is a preview of subscription content, log in via an institution to check access.
References
Bevan, E. R., Jones, A. M. & Hawkey, P. M. Global epidemiology of CTX-M β-lactamases: temporal and geographical shifts in genotype. J. Antimicrob.Chemother. 72, 2145–2155 (2017).
Basarab, G. S. et al. Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. Sci. Rep. 5, 11827 (2015).
Fisher, J. F. & Mobashery, S. Endless resistance. Endless antibiotics? Medchemcomm 7, 37–49 (2016).
Richter, M. F. et al. Predictive compound accumulation rules yield a broad-spectrum antibiotic. Nature 545, 299–304 (2017).
Llewelyn M. J. et al. The antibiotic course has had its day. BMJ 358, j3418 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Related links
Related links
FURTHER INFORMATION
European Union Joint Programming Initiative on Antimicrobial Resistance
Rights and permissions
About this article
Cite this article
Piddock, L. Understanding drug resistance will improve the treatment of bacterial infections. Nat Rev Microbiol 15, 639–640 (2017). https://doi.org/10.1038/nrmicro.2017.121
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrmicro.2017.121
- Springer Nature Limited
This article is cited by
-
Antibacterial Alternatives to a Dying Antibiotic Pipeline
Current Treatment Options in Infectious Diseases (2023)
-
Anti-quorum sensing activity of Forsythia suspense extract against Chromobacterium violaceum by targeting CviR receptor
International Microbiology (2020)